Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study

19 Mar 2024

Abstract excerpt

BACKGROUND & AIMS: Glucose-lowering drug is associated with various cancers, but the causality with gastrointestinal cancer risk is rarely reported. We aimed to explore the causality between them in this Mendelian randomization (MR) study. METHODS: Two-sample MR, summary-data-based (SMR), mediation MR, and colocalization analyses was employed. Ten glucose-lowering drug targets (PPARG, DPP4, GLP1R, INSR, SLC5A2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Associations and Epidemiology
Share to Genetic factors in colorectal cancer
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38504335
DOI: 10.1186/s13578-024-01214-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization studyPMID 38504335Read ↗

Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study.Semantic proximity Read ↗

Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.Semantic proximity Read ↗

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.Semantic proximity Read ↗

35 blood and urine biomarkers and digestive system cancers: A two-sample Mendelian randomization study.Semantic proximity Read ↗

Exploring the causality and pathogenesis of Type 2 diabetes in gastric cancer based on Mendelian randomization and transcriptome data analysesSemantic proximity Read ↗

Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease.Semantic proximity Read ↗

Smoking, alcohol consumption, diabetes, body mass index, and peptic ulcer risk: A two-sample Mendelian randomization studySemantic proximity Read ↗

Causal linkage between type 2 diabetes mellitus and inflammatory bowel disease: an integrated Mendelian randomization study and bioinformatics analysisSemantic proximity Read ↗

Casual effects of type 1 diabetes mellitus on site-specific digestive cancers: a Mendelian randomisation analysis.Semantic proximity Read ↗

Causality between six psychiatric disorders and digestive tract cancers risk: a two-sample Mendelian randomization study.Semantic proximity Read ↗

Novel Insights into the Relationship Between Glucose-Lowering Drugs and Nonalcoholic Fatty Liver Disease and liver function: a Mendelian Randomization StudySemantic proximity Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.